| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| FAST LINE HOLDING Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 39,765 | -0,85 % | Chancen und Kontraste am Markt: Novo Nordisk mit Abnehmpille, ASIC-Sorgen bei DroneShield, Power Metallic Mines mit Ausbruchsmöglichkeit | Der dänische Pharmagigant Novo Nordisk musste im erbitterten Wettlauf um die lukrative Abnehmspritze einen empfindlichen Dämpfer hinnehmen, aber jetzt kommt die Abnehmpille als Wunderwaffe. Gleichzeitig... ► Artikel lesen | |
| AURORA CANNABIS | 3,362 | -1,00 % | Curaleaf Holdings, Inc.: Curaleaf Responds to Aurora Cannabis Circular; Reaffirms Offer as the Best Path to Value Creation for Shareholders | Highlights
Curaleaf Offers a 45% Premium and Meaningful Future Upside: Aurora shareholders can realize immediate value alongside the opportunity to participate... ► Artikel lesen | |
| CANOPY GROWTH | 0,832 | -0,19 % | Canopy Growth's Revenue Grew 13% Last Quarter. Investors Barely Reacted. Here's Why. | ||
| TILRAY BRANDS | 3,835 | -0,90 % | Tilray Brands, Inc.: Award-Winning BrewDog Unleashes Liquid Visions, a Bold New Craft Beer Series Built to Light Up Retail Shelves | Fresh from multiple wins at the 2026 World Beer Awards, BrewDog brings a major new premium craft beer innovation to market through a nationwide retail rollout.
Four art-led beers, big hop character... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 465,00 | -1,13 % | Vertex Pharmaceuticals Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team | Crinetics acquisition completed September 1, 2026
Charles Wagner, EVP, Chief Operating and Financial Officer to take on expanded COO role overseeing integration of Crinetics, effective immediately
As... ► Artikel lesen | |
| ARZNEIWERK AG VIDA | 0,176 | -6,88 % | EQS-HV: Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 02.09.2026 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: Arzneiwerk AG VIDA
/ Bekanntmachung der Einberufung zur Hauptversammlung
Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 02.09.2026 in Berlin... ► Artikel lesen | |
| CRONOS GROUP | 2,772 | -0,29 % | Cronos Group Inc.: Cronos Group Reports 2026 Second Quarter Results | Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q2 2026 increased by 51% year-over-year on an organic, constant-currency basis... ► Artikel lesen | |
| DIGICANN VENTURES | 0,016 | +128,57 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,966 | -0,62 % | ORGANIGRAM GLOBAL INC. - 6-K, Report of foreign issuer | ||
| GREEN THUMB INDUSTRIES | 6,500 | -1,66 % | Green Thumb Industries Has Hit a Rough Patch. Here's Why Its Best Days Could Be Ahead. | ||
| NOVERIS HEALTH SCIENCES | 0,075 | -20,63 % | Noveris Health Sciences Inc.: Noveris Health Sciences Announces Proposed Private Placement of Convertible Debentures for up to $500,000 | Vancouver, British Columbia--(Newsfile Corp. - August 20, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") is pleased to announce its intention... ► Artikel lesen | |
| SANTHERA PHARMACEUTICALS | 16,420 | -1,32 % | Santhera Pharmaceuticals Holding AG: Santhera Expands Biomedica Agreement to Extend AGAMREE (Vamorolone) Distribution Across Central Asia and the Caucasus | Pratteln, Switzerland, July 13, 2026 - Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE (vamorolone), extending the... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 62,70 | -1,69 % | Nektar Therapeutics Announces Second Quarter 2026 Financial Results | SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| AMARIN | 11,700 | -0,85 % | Amarin Corporation plc: Amarin Highlights New REDUCE-IT and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 | ||
| FILANA THERAPEUTICS | 0,674 | -3,58 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen |